



The frequency and clinical significance of DNA polymerase beta (POL β) expression in breast ductal carcinoma in situ (DCIS)

Abdulbaqi Al-Kawaz^{1,2} · Reem Ali¹ · Michael S. Toss¹ · Islam M. Miligy^{1,3} · Omar J. Mohammed¹ · Andrew R. Green¹ · Srinivasan Madhusudan¹ · Emad A. Rakha^{1,3,4}

Received: 4 May 2021 / Accepted: 6 August 2021 / Published online: 18 August 2021
© Crown 2021

Abstract

Background The prediction of clinical behaviour of breast ductal carcinoma in situ (DCIS) and its progression to invasive disease remains a challenge. Alterations of DNA damage repair mechanisms are associated with invasive breast cancer (BC). This study aims to assess the role of base excision repair (BER) DNA Polymerase Beta (POL β) in DCIS.

Methods A cohort of DCIS comprising pure DCIS ($n = 776$) and DCIS coexisting with invasive BC ($n = 239$) were prepared as tissue microarrays. POL β protein expression was assessed using immunohistochemistry and correlated with clinicopathological parameters and patient outcome. Preclinically, we investigated the impact of POL β depletion on stem cell markers in representative DCIS cell line models.

Results Reduced POL β expression was associated with aggressive DCIS features including high nuclear grade, comedo necrosis, larger tumour size, hormonal receptor negativity, HER2 overexpression and high Ki67 index. Combined low nuclear/low cytoplasmic POL β expression showed the strongest association with the features' characteristics of aggressive behaviour. There was a gradual reduction in the POL β expression from normal breast tissue, to DCIS, with the lowest expression observed in the invasive BC. Low POL β expression was an independent predictor of recurrence in DCIS patients treated with breast conserving surgery (BCS). POL β knockdown was associated with a significant increase in cell stemness markers including SOX2, NANOG and OCT4 levels in MCF10-DCIS cell lines.

Conclusion Loss of POL β in DCIS is associated with aggressive behaviour and it can predict recurrence. POL β expression in DCIS provides an additional feature for patients' risk stratification for personalised therapy.

Keywords DCIS · Breast cancer · POL β · DNA damage response · Prognosis

Introduction

Breast cancer (BC) carcinogenesis is a multistep process that involves genetic and epigenetic changes which leads to gradually develops invasive breast cancer (IBC). This multistep

process transforms normal ductal cells pre-invasive lesions and eventually into invasive disease [1]. In breast ductal carcinoma in situ (DCIS) the malignant epithelial cells are morphologically and genetically similar to their invasive BC counterparts, but they are confined within the mammary duct system. Prediction of DCIS progression to invasive disease or recurrence after initial excision remains a challenge [2].

The maintenance of genomic integrity is achieved by DNA protection from damage that could be induced by endogenous or exogenous factors [3]. DNA damage repair (DDR) is a complex mechanism and depends on the interaction between the various pathways [4]. Carcinogenesis is driven by impaired DNA repair [5–7]. DNA polymerase β (POL β) is one of the DNA polymerase groups that appear to have paramount significance in genome integrity preservation [8–10]. Bases that have been damaged by oxidation, alkylation or ring saturation must be removed accurately

✉ Emad A. Rakha
emad.rakha@nottingham.ac.uk; Emad.rakha@nuh.nhs.uk

¹ Division of Cancer and Stem Cells, School of Medicine, The University of Nottingham, Nottingham, UK

² Department of Pathology, College of Dentistry, Al Mustansiriya University, Baghdad, Iraq

³ Department of Pathology, Faculty of Medicine, Menoufia University, Menoufia, Egypt

⁴ Department of Histopathology, Nottingham University Hospital NHS Trust, City Hospital Campus, Hucknall Road, Nottingham NG5 1PB, UK

by the base excision repair (BER) pathway [11]. POL β is recruited to the impaired cells by cooperating with the BER scaffold protein (XRCC1) and the DNA damage repair protein (PARP1) [12–14]. POL β is localised on chromosome 8p11 and it is a hot spot for chromosomal deletion and alterations associated with different types of cancers including BC [15–19]. Mutation in POL β raises the mutation frequency which promotes carcinogenesis [20–22].

In this study, we hypothesised that POL β provides prognostic and predictive value in DCIS. We utilised a large well-characterised cohort of DCIS to assess the clinical and molecular significance of POL β expression in DCIS and determine its association with the disease progression.

Materials and methods

Study cohort

This retrospective study was carried out on a successive series of 1015 DCIS cases comprising pure DCIS ($n = 776$) and DCIS with synchronous invasive BC (DCIS mixed; $n = 239$) diagnosed and treated at the Breast Institute, City Hospital, Nottingham, United Kingdom. The demographic and histopathological data including age at diagnosis, mode of disease presentation (symptomatic or screen-detected), DCIS size, nuclear grade, the presence of necrosis and postoperative radiotherapy (RT), were collected. Molecular classification based on the expression of hormonal receptors [oestrogen and progesterone receptor (ER&PR)], HER2 status and Ki-67 proliferation index were available as previously described [23]. ER&PR positivity was defined when the positive nuclei of tumour cells were $\geq 1\%$ [24]. Herceptin test method was used to assess HER2 where IHC score of 0 or 1 considered as negative, 2+ considered as equivocal and 3+ considered as positive [25]. Moreover, the Ki-67 proliferation index was defined as high if its nuclear expression in malignant epithelial cells was more than 14% [23] (Supplementary Table S1). Local recurrence-free interval (LRFI) was defined as the time between the primary surgical excision to the time of development ipsilateral recurrence as DCIS or invasive BC. Cases with contralateral breast cancer were censored at the time of development of the contralateral event.

Analysis of POL β mRNA in invasive BC

Due to the limited availability of transcriptomic data of the DCIS, the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) ($n = 1980$) data were used to validate the clinical and prognostic significance of POL β in invasive BC [26].

Evaluation of POL β protein expression

Western blotting was performed to validate the anti-POL β antibody specificity (Abcam; rabbit polyclonal ab26343. Lot No. GR 284,224–3). A panel of human cell lysates was used including MCF10DCIS, MCF7, MCF10A and MDA-MB-231. They were purchased from the American Type Culture Collection (Rockville, MD, USA). A single specific band at the predicted size of 38 kDa was achieved using an antibody dilution at 1:1000 and incubated overnight at 4 °C. Anti-beta tubulin (mouse monoclonal anti-beta tubulin antibody Abcam) 55 kDa was included in the Western Blot as a loading control (Fig. 1A).

The assessment of the expression of POL β protein in DCIS by immunohistochemistry (IHC) was conducted on 4 μ m tissue microarray sections (TMA) and full-face tissue Sects. (10 cases) of formalin-fixed paraffin-embedded (FFPE) blocks using the Novocastra Novolink polymer detection system (Leica, Newcastle, UK) following the manufacturer's guidelines. Subsequently, samples were incubated for 30 min at room temperature with the POL β primary antibody optimally diluted in 1:500 in the Leica antibody diluent (Supplementary material and method S1, S2).

The scoring, based on a semi-quantitative histochemical assessment scoring method (*H*-Score), was conducted on POL β nuclear and cytoplasmic expression. H-score took into consideration the staining intensity (negative, weak, moderate and strong expression as 0, 1, 2 and 3, respectively) and the percentage of the stained tumour cells. The result of scoring was gained by multiplying the intensity of staining by the percentage of expression in the nucleus and cytoplasm of the tumour cells. The score was expressed in a range of 0–300 [27]. All cores with less than 15% tumour were excluded from scoring. DCIS component and invasive component in DCIS mixed with invasive were scored separately. Moreover, whenever present in the tissue cores, expression of POL β within the adjacent normal terminal ductal lobular unit (TDLUs) was also assessed ($n = 50$). X-tile (X-tile Bioinformatics software, Yale University, version 3.6.1) was used to dichotomise the nuclear POL β expression into high (*H*-score > 130) and low, and cytoplasmic expression into high (*H*-score > 60) and low according to patient outcome in the pure DCIS cohort [28, 29]. Scoring has been done blindly to clinicopathological data and patient outcome. Approximately 30% of cases were double scored by another pathologist and the discrepant cases were reviewed by both observers and a final score was agreed.




Fig. 1 POL- β Western blot and IHC protein expression. **A** Western blot for POL- β antibody showed a single band at the predicted molecular weight 38 kDa in the cell lysates MCF7, MCF10A, MDA-MB231 and MCF10-DCIS, respectively (green bands). Tubulin used as an internal loading control and shows a single band as a standard control (red band) at the predicted molecular weight 55 kDa in all cell lysates. W.B chart was presented the higher level of POL- β protein

was expressed in MCF10A, MCF7, MCF10DCIS, and MDA-MB231, respectively. **B–F** POL- β protein expression in DCIS. **B** Normal terminal ductal lobular units, lined by single layer of epithelial cells (X10). **C** Negative IHC expression (X20). **D** Strong IHC expression in DCIS (X20). **E** Weak to moderate IHC expression in IBC component (X20). **F** Mixed DCIS coexistent with IBC (X10)

POL β siRNA knockdown (KD) in DCIS cells

MCF10DCIS cells were a gift from prof. Vimla band laboratory. MCF10DCIS BC cell line was previously derived from a xenograft originating from premalignant MCF10AT cells injected into SCID mice [30]. Injection of the MCF10DCIS cells into SCID mice results in a predominantly comedo DCIS phenotype [30, 31]. MCF10A, MCF-7 and MDA-MB231 breast cancer cell lines were purchased from ATCC. MCF10DCIS and MCF10A cell lines were cultured in DMEM-F12 supplemented with 10% horse serum, 5 mg/ml insulin, 1 mg/ml cholera toxin, and 100 μ g/mL

EGFR, 5 mg/mL hydrocortisone and 1% penicillin–streptomycin. MDA-MB231 and MCF-7 cells were cultured in minimum essential amino acids medium supplemented with 10% FBS, 1% penicillin–streptomycin, 1% L-glutamine and 1% nonessential amino acids. POL β siRNA were obtained from Invitrogen, UK (catalogue no. 4390824, ID: S10776). Briefly, 1×10^6 Cells were seeded in T25 cell culture flasks overnight. siRNA constructs were transfected using Lipofectamine 3000 reagent (Invitrogen, UK) (catalogue no. L3000001) as per the manufacturer’s protocol in Opti-MEM low serum medium (catalogue no. 11058021). Transfection efficiency was confirmed on day 3, day 5 and day 7 using

western blotting. Evaluation of N-cadherin, C-MYC, OCT4, NANOG, SOX2, MMP-9 and ALDH1 protein expression was performed by western blotting on extracts of MCF10-DCIS POL β control and MCF10-DCIS POL β _KD.

Statistical analysis

Statistical analysis was conducted using SPSS software version 24 (Chicago, IL, USA). Relevant statistical analyses have been carried out based on the distribution of data (parametric or non-parametric). Association between POL β mRNA expression with clinicopathological parameters and outcome was carried out in the METABRIC database. Chi Square, Mann–Whitney and Kruskal Wallis tests were used to evaluate the correlation of clinicopathological parameters with the expression of POL β protein level. Wilcoxon signed test was used to compare POL β protein level in the TDLUs and DCIS. Whilst Mann–Witney was used to compare POL β protein level in pure DCIS and DCIS component coexistent with IBC. To compare between DCIS component and invasive component in mixed cases, Wilcoxon Signed Ranks Test was used. Log rank and Kaplan Meier tests were used to perform the outcome analysis. p -value < 0.05 was considered significant.

Ethical approval was obtained by North West Manchester Ethics Committee under the title “Nottingham Health Science Biobank (15/NW/0685)”.

The reporting recommendation for tumour markers prognostic studies (REMARK) criteria was used in this study.

Results

POL β protein expression

Stained full-face sections ($n = 10$) of DCIS and DCIS coexistent with invasive disease showed a homogenous distribution of POL β expression which demonstrated the efficiency of using the TMA sections to evaluate POL β expression. POL β was expressed in nuclei of the TDLUs and tumour cells with variable intensities. Occasional weak to moderate staining in the cytoplasm of tumour cells was also noticed.

POL β protein expression showed unimodal, non-parametric distribution amongst the study cohort where the median H -score for the nuclear POL β expression was 130 (range 0–270) and for cytoplasmic expression was 60 (range 0–240). Interestingly, these figures were similar to the cut-off points identified by the X-tile software to stratify the cases according to outcome. Based on these cut-off points, high nuclear POL β expression was observed in 388/465 cases (83%) whilst low cytoplasmic POL β expression was observed in 322/465 cases (69%).

POL β expression in the mixed DCIS cohort

In the DCIS component in the DCIS-mixed cohort, positive nuclear staining was recognised in 189/198 cases (95%). Furthermore, positive cytoplasmic expression was recognised in 179/198 cases (90%). The median H -score for nuclear POL β expression in the DCIS component was 100 (range 0–220) and the median H -score for nuclear POL β expression in the invasive component was 90 (range 0–180). For the cytoplasmic expression in the DCIS component, the median H -score was 60 (range 0–130). Low POL β nuclear expression was observed in 46 out of 194 cases (76%), whilst low cytoplasmic expression was observed in 139/194 cases (72%) in the DCIS component.

Low nuclear expression was observed in 72 out of 222 cases (32%) of invasive component of the mixed cohort. However, 139/194 cases (72%) representing low cytoplasmic expression were seen in the mixed DCIS coexistent with IBC of the mixed cohort (Fig. 1B–F).

POL β protein expression levels were higher in the nuclei of TDLUs compared with the pure DCIS ($p = 0.002$). The level of nuclear POL β expression in the pure DCIS was higher than the DCIS component coexistent with invasive cancer ($p < 0.001$). Moreover, the nuclear POL β expression in the DCIS component coexistent with invasive in the mixed cohort was higher than the invasive component ($p = 0.002$). The nuclear intensity expression was greater in the TDLUs compare with the invasive component ($p < 0.001$) (Fig. 2).

The association between POL β expression and clinicopathological parameters

Low nuclear POL β protein expression in pure DCIS cohort was associated with aggressive clinicopathological parameters, including high nuclear grade ($p = 0.001$), comedo necrosis ($p = 0.006$), negative hormonal status ($p < 0.001$), positive HER2 status ($p = 0.005$) and with HER2 in molecular subtypes ($p < 0.001$) (Table 1). There was a significant association of low nuclear POL β expression with large DCIS size ($p = 0.018$) and high proliferative index Ki-67 ($p = 0.008$) (Supplementary Table S2). Low cytoplasmic POL β expression was significantly associated with larger DCIS size ($p = 0.017$), diffused type of DCIS ($p = 0.025$) high nuclear grade ($p = 0.015$), PR negativity ($p = 0.046$), HER2 positivity ($p = 0.007$) and higher proliferation index (Ki67) ($p = 0.021$) (Table 2 and Supplementary Table S3).

Low POL β nuclear expression in DCIS-mixed cohort was significantly associated with larger tumour size ($p = 0.022$), high nuclear grade ($p = 0.025$), comedo necrosis ($p = 0.002$), negative oestrogen receptor ($p = 0.001$) and with patients treated with mastectomy ($p = 0.023$). Results were confirmed by continuous data analysis (Table 3). Additionally, low cytoplasmic POL β expression was associated




Fig. 2 POL- β nuclear protein expression boxplot. POL- β nuclear protein expression boxplot showing the highest level of POL- β nuclear protein expression in the normal TDLUs, decreased to the lowest level in the IBC component of the mixed IBC series

with high nuclear grade ($p=0.034$), presence of comedo necrosis (0.018) and negative oestrogen receptor ($p=0.018$). Similar results were obtained by analysis of continuous data (Table 4).

POL β nuclear/cytoplasmic (N/C) protein co-expression has been investigated in the DCIS cohort. 29% demonstrated high nuclear/high cytoplasmic expression (H.N/H.C), 54% showed H.N/L.C, 15% with L.N/L.C and 2% demonstrated L.N/H.C.

The L.N/L.C cluster was significantly associated with aggressive behaviour including high nuclear grade ($p=0.003$), presence of comedo necrosis ($p=0.026$), and larger size of DCIS ($p=0.010$). However, the low protein expression of POL β (L.N/L.C cluster) was observed more in the ER positive ($p=0.001$) and HER2 negative ($p=0.004$) tumours and in the luminal A molecular subgroup compared to other molecular subgroups ($p<0.001$) (Table 5).

METABRIC cohort

Low *POL β* mRNA expression was associated with young patient age ($p=0.001$), premenopausal status ($p=0.015$), high tumour grade ($p<0.001$), negative hormonal status (ER&PR) ($p<0.001$), positive HER2 status ($p<0.001$) and basal-like breast cancer molecular subtype ($p<0.001$) (Supplementary Table S4). Moreover, low *POL β* mRNA expression was associated with shorter BCSS ($p<0.001$, HR=0.720, 95% CI 0.604–0.859) (Fig. 3A).

Association of POL β and patient outcome

Low nuclear expression of POL β in the DCIS was significantly associated with poor outcome in the form of shorter LRFI for all recurrences (in situ recurrence and invasive recurrence) ($p=0.041$, HR=0.530, 95% CI 0.287–0.976) (Fig. 3B). A significant association was observed in patients who underwent BCS without adjuvant radiotherapy (RT) ($p=0.018$, HR=0.433, 95% CI 0.217–0.865), as well as in patients treated with BCS and received adjuvant radiotherapy (BCS + RT) ($p=0.041$, HR=0.528, 95% CI 0.287–0.973) (Fig. 3C and D respectively).

Although POL β cytoplasmic expression in pure DCIS did not show significant associations with patient outcome, combined analysis of N/C expression revealed that L.N/L.C cluster was associated with shorter LRFI ($p=0.022$, HR=2.234, 95% CI 1.125–4.436) (Fig. 3E).

Low expression of POL β nuclear protein in DCIS was an independent predictor of a poor outcome in DCIS when plotted against patient age, DCIS size, nuclear grade, radio-therapeutic treatment, HER2 status and proliferation index Ki67 ($p=0.031$, HR=0.490, 95% CI 0.256–0.936) (Table 6). Cytoplasmic POL β expression but did not reveal any significant association as a predictor of patient outcome.

Functional studies

POL β depletion and stemness phenotype in MCF10-DCIS cell line: The clinical data shown here suggest that downregulation of POL β is associated with aggressive breast cancer pathogenesis. Therefore, we hypothesised that POL β depletion could be associated with increased stemness in DCIS

Table 1 Correlation between nuclear POL-β protein expression and clinicopathological parameters in pure DCIS cohort using categorical values

Parameters	Low exp No. (%)	High exp No. (%)	Total No. (%)	(χ^2) <i>p</i> -value
Age (Years)				
≤ 50	20 (17.0)	96 (83.0)	116 (25.0)	(0.052)
> 50	57 (16.0)	292 (84.0)	349 (75.0)	0.820
Size ^a				
< 16 mm	21 (15.0)	124 (72.0)	145 (31.0)	(1.239)
16–40 mm	30 (16.0)	154 (84.0)	184 (40.0)	0.538
> 40 mm	26 (19.0)	108 (81.0)	134 (29.0)	
DCIS presentation				
Screening	34 (15.0)	192 (85.0)	226 (49.0)	(0.730)
Symptomatic	43(18.0)	196 (82.0)	239 (51.0)	0.393
Nuclear grade				
Low	4 (7.0)	57 (93.0)	61 (13.0)	(13.391)
Moderate	12 (10.0)	109 (90.0)	121 (26.0)	0.001
High	61 (22.0)	222 (78.0)	283 (61.0)	
Comedo necrosis				
No	17 (10.0)	150 (90.0)	167 (39.0)	(7.676)
Yes	60 (20.0)	238 (80.0)	283 (61.0)	0.006
Oestrogen status				
Negative	31 (28.0)	81 (72.0)	112 (26.0)	(13.414)
Positive	41 (13.0)	281(87.0)	322 (74.0)	< 0.001
Progesterone status				
Negative	47 (26.0)	135 (74.0)	182 (41.0)	(20.463)
Positive	25 (10.0)	234 (90.0)	259 (59.0)	< 0.001
Her2 status				
Negative	43 (13.0)	281 (87.0)	324 (77.0)	(8.068)
Positive	25 (25.0)	74 (75.0)	99 (23.0)	0.005
Proliferation index (Ki 67)				
Low (< 14%)	47 (15.0)	266 (85.0)	313 (77.0)	(2.191)
High (≥ 14%)	20 (22.0)	73 (78.0)	93 (23.0)	0.139
Molecular classes				
Luminal A	21 (11.0)	170 (89.0)	191 (51.0)	(18.926)
Luminal B	11 (14.0)	69 (86.0)	80 (21.0)	< 0.001
Her2	16 (37.0)	27 (63.0)	43 (11.0)	
Triple negative	12 (20.0)	84 (80.0)	60 (16.0)	

Significant *p*-values are in bold

No number, χ^2 Chi square, *POL-β* DNA polymerase beta, *DCIS* ductal carcinoma in situ, *HER2* human epidermal growth factor receptor 2

^aSize: based on Van Nuys Prognostic Index (VNPI)

leading to aggressive phenotype. We showed that MCF10-DCIS cells are non-invasive cell line, similar to MCF10A non-cancerous epithelial cells [32]. We performed POLβ knockdown by siRNA in MCF10-DCIS cells. We observed a robust knockdown of POLβ in our cells in day 3, 5 and 7, the most depleted level of POLβ protein level was observed

Table 2 Correlation between cytoplasmic POL-β expression in DCIS with clinicopathological parameters in pure DCIS cohort using categorical values

Parameters	Low exp No. (%)	High exp No. (%)	Total No. (%)	(χ^2) <i>p</i> -value
Age (years)				
≤ 50	86 (74.0)	30 (56.0)	116 (25.0)	(1.736)
> 50	236 (6.0)	113 (32.0)	349 (75.0)	0.188
Size ^a				
< 16 mm	88 (61.0)	57 (39.0)	145 (31.0)	(8.169)
16–40 mm	133 (72.0)	51 (28.0)	184 (40.0)	0.017
> 40 mm	101 (75.0)	33 (25.0)	134 (29.0)	
DCIS presentation				
Screening	159 (70.0)	67 (30.0)	226 (49.0)	(0.253)
Symptomatic	163 (68.0)	76 (32.0)	239 (51.0)	0.615
Nuclear grade				
Low	37 (61.0)	24 (39.0)	61 (13.0)	(8.379)
Moderate	75 (62.0)	46 (38.0)	121 (26.0)	0.015
High	210 (74.0)	73 (26.0)	283 (61.0)	
Comedo necrosis				
No	109 (65.0)	58 (35.0)	167 (36.0)	(1.936)
Yes	21 (71.0)	85 (29.0)	298 (64.0)	0.164
Oestrogen status				
Negative	84 (75.0)	28 (25.0)	112 (26.0)	(3.013)
Positive	213 (66.0)	109 (34.0)	322 (74.0)	0.083
Progesterone status				
Negative	135 (74.0)	47 (26.0)	182 (41.0)	(3.976)
Positive	169 (65.0)	90 (35.0)	259 (59.0)	0.046
Her2 status				
Negative	212 (65.0)	112 (35.0)	324 (77.0)	(7.290)
Positive	79 (80.0)	20 (20.0)	99 (23.0)	0.007
Proliferation index (Ki 67)				
Low (< 14%)	210 (67.0)	103 (33.0)	313 (77.0)	(5.310)
High (≥ 14%)	74 (80.0)	19 (20.0)	93 (23.0)	0.021
Molecular classes				
Luminal A	127 (66.0)	64 (34.0)	191 (51.0)	(6.852)
Luminal B	55 (69.0)	25 (31.0)	80 (21.0)	0.077
Her2	37 (86.0)	6 (14.0)	43 (12.0)	
Triple negative	39 (65.0)	21 (35.0)	60 (16.0)	

Significant *p*-values are in bold

No number, χ^2 Chi square, *POL-β* DNA polymerase beta, *DCIS* ductal carcinoma in situ, *HER2* Human epidermal growth factor receptor 2, *LCIS* lobular carcinoma in situ, *BCS* Breast conserving

^aSize: based on Van Nuys Prognostic Index (VNPI)

in day 7 (Fig. 4A). We evaluated the expression of well identified stem cells markers in MCF10DCIS_POLβ_KD cells compared to controls. Interestingly, MCF10-DCIS_POLβ_KD cells have a noticeable increase in C-MYC, OCT4, NANOG and SOX2 protein expression (Fig. 4B–E respectively) suggesting that MCF10-DCIS_POLβ_KD acquired

Table 3 Correlation between $POL\beta$ nuclear protein expression in DCIS component in mixed cohort

Parameters	Categorical values			Continuous values			
	Low exp No. (%)	High exp No. (%)	Total No. (%)	(χ^2) <i>p</i> -value	No. of cases	Mean rank	(χ^2) <i>p</i> -value
Age (years)							
≤ 50	23 (25.0)	71 (75.0)	94 (48.0)	0.058	94	94.22	0.429
> 50	23 (23.0)	77 (77.0)	100 (52.0)	0.810	100	100.58	
Size ^a							
< 16 mm	19 (22.0)	69 (78.0)	88 (45.0)	7.678	88	101.53	0.197
16–40 mm	21 (22.0)	75 (78.0)	96 (50.0)	0.022	96	96.88	
> 40 mm	6 (60.0)	4 (40.0)	10 (5.0)		10	67.95	
Nuclear grade							
Low	1 (10.0)	9 (90.0)	10 (5.0)	7.355	10	137.75	< 0.001
Moderate	5 (11.0)	41 (89.0)	46 (24.0)	0.025	46	119.10	
High	40 (29.0)	98 (71.0)	138(71.0)		138	87.38	
Comedo necrosis							
No	3 (7.0)	42 (93.0)	45 (23.0)	9.410	45	132.66	< 0.001
Yes	43 (29.0)	106(71.0)	149(77.0)	0.002	149	86.88	
Oestrogen status							
Negative	10 (53.0)	9 (47.0)	19 (10.0)	10.130	19	59.42	0.002
Positive	35 (20.0)	139 (80.0)	174 (90.0)	0.001	174	101.10	
Final operation							
Mastectomy	29 (31.0)	65 (69.0)	94 (48.0)	5.139	94	88.63	0.032
BCS	17 (17.0)	83 (83.0)	100(52.0)	0.023	100	105.84	

Significant *p*-values are in bold

No number, χ^2 Chi square, $POL\beta$ DNA polymerase beta, DCIS ductal carcinoma in situ, BCS breast conserving, BCS breast conserving surgery

^aSize: based on Van Nuys Prognostic Index (VNPI)

stemness phenotype associated cancerous self-renewal and increased cell division. However, MCF10-DCIS_ $POL\beta$ _KD cells has a noticeable decrease in ALDH1 and no changes in N-cadherin and MMP-9 protein levels were observed in MCF10-DCIS_ $POL\beta$ _KD cells (Fig. 4F–H respectively).

Discussion

Although breast cancer is a heterogeneous disease, there is a great similarity between DCIS and invasive carcinoma at histological and molecular levels. DNA damage repair is a complex mechanism that depends on the interaction between the various pathways to repair impaired DNA. The mechanisms of DNA repair act as a barrier to maintain genetic stability as well as preventing cancer development. Following DNA damage, one or more repair pathways are activated, such as BER. $POL\beta$ is one of the most important DNA polymerases in BER as it contributes to genome stability maintenance [16, 33]. The role of the $POL\beta$ gene has been studied in many different tumours [16, 17, 27, 34–37]. In this study, $POL\beta$ low expression in the METABRIC cohort showed a

significant association with an aggressive phenotype. This indicates the tumour suppressor role of $POL\beta$ in BC.

This study aimed to evaluate the expression of $POL\beta$ in a large DCIS cohort, as well as a DCIS-mixed cohort. The data provide evidence that $POL\beta$ might have a crucial role in DCIS genomic stability. Starcevic et al. [38] reported that one-third of total tumours examined expressed $POL\beta$ variant proteins and could induce genomic instability. Our data showed an association between low $POL\beta$ expression and aggressive DCIS phenotypes such as a high nuclear grade, which is consistent with Chantre-Justino et al. [33]. BER transcript profiling based on grade demonstrated differences in the molecular signature between the high and low-grade tumours, which is referred to as differential transcriptional regulation suggesting that BER dysregulation could promote carcinogenesis. $POL\beta$ gene has a misalignment-mediated mutator activity associated with aggressive mutator phenotype [38, 39]. It has been reported that cells with reduced expression of $POL\beta$ protein accumulate DNA damage and aggressive cancerous phenotype may be driven by mutation and genomic instability that result from impaired BER [40]. Moreover, increased $POL\beta$ expression proved to be

Table 4 Correlation between POL β cytoplasmic protein expression in DCIS component in mixed cohort

Parameters	Categorical values				Continuous values		
	Low exp No. (%)	High exp No. (%)	Total No. (%)	(χ^2) <i>p</i> value	No. of cases	Mean rank	(χ^2) <i>p</i> value
Age (years)							
≤ 50	69 (73.0)	25 (27.0)	94 (48.0)	0.058	94	93.61	0.346
> 50	70 (70.0)	30 (30.0)	100(52.0)	0.810	100	101.16	
Size ^a							
< 16 mm	59 (67.0)	29 (33.0)	88 (45.0)	2.828	88	100.02	0.364
16–40 mm	71 (74.0)	25 (26.0)	96 (50.0)	0.243	96	97.68	
> 40 mm	9 (90.0)	1 (10.0)	10 (5.0)		10	73.55	
Nuclear grade							
Low	6 (60.0)	4 (40.0)	10 (5.0)	6.278	10	113.65	0.013
Moderate	27 (27.0)	19 (41.0)	46 (24.0)	0.034	46	116.45	
High	106(77.0)	32 (23.0)	138(71.0)		138	90.01	
Comedo necrosis							
No	26 (58.0)	19 (42.0)	45 (25.0)	5.550	45	117.66	0.006
Yes	113(76.0)	36 (24.0)	149(75.0)	0.018	149	91.41	
Oestrogen status							
Negative	18 (95.0)	1 (5.0)	19 (10.0)	5.583	19	81.00	0.186
Positive	120(69.0)	54(31.0)	174(90.0)	0.018	174	98.75	
Final operation							
Mastectomy	73 (78.0)	21 (22.0)	94 (48.0)	3.243	94	88.63	0.032
BCS	66(66.0)	34 (34.0)	100(52.0)	0.072	100	105.84	

Significant *p*-values are in bold. Mean rank operated by MannWhitey test and Kurskal test

POL- β DNA polymerase beta, DCIS ductal carcinoma in situ, Her2 human epidermal growth factor receptor 2, BCS breast conserving

^aSize: based on Van Nuys Prognostic Index (VNPI)

resistant to DNA damage. These results suggest that POL β can act as a caretaker gene where its absence associates with aggressive behaviour [41]. Our results showed that negative ER expression is associated with aggressive behaviour. Mobbley and Brueggemeier [42] reported that oestrogen evolves to carcinogenesis in the breast by creating a link that connects oestrogen-induced BC and an oxidative stress pathway. Moreover, there is a robust relationship between ER responsiveness and oxidative DNA damage that is significantly elevated by approximately ten-fold in the invasive BC compared to normal breast tissue and about three-fold higher in positive ER than negative ER BC [43]. Bhat et al. [44] mentioned that oestrogen could promote carcinogenicity by inducing oxidative stress. Interestingly, our results showed that low nuclear POL β level was associated with ER negative cases which probably suggests that non oestrogen mediated oxidative stress pathways trigger DNA damage and particularly involve in DCIS.

Following our result, it has been found that amplified Her2 was associated significantly with aggressive behaviour and poor prognosis in breast cancer [25, 45]. Notably, expression of the HER2 level was different within various stages of BC progression. In general, Her2 in TDLUs was

rarely detected in atypical ductal hyperplasia (ADH) but was amplified or overexpressed in high nuclear grade DCIS, especially in types of comedo necrosis and in a high nuclear grade of IBC. A loss of, or undetectable, Her2 protein levels in benign lesions suggests that its amplification or overexpression occurs in the transition from hyperplasia to DCIS, suggesting that overexpression is considered significant in early malignant progression [46]. It is therefore noticeable that the trend of decreasing POL β occurs simultaneously with increasing HER2 expression when tumour aggressiveness increases. However, it is hard to conclude whether there is direct or indirect crosstalk between these two proteins as further molecular investigations required.

In this study, we explored the level of POL β nuclear protein in a comparative cohort (mixed DCIS/IBC cohort). Our observations showed that a decreasing trend of POL β levels was demonstrated starting from TDLUs, pure DCIS series, DCIS component coexisting with invasive disease and invasive component which showed the lowest level of POL β protein in the study cohort. This observation supports the notion of our hypothesis which states that the lack, or loss, of the POL β protein associates with aggressive DCIS phenotype.

Table 5 The correlation between Nuclear/Cytoplasmic (clustering) POLB expression in pure DCIS cohort with clinicopathological parameters

Parameters	H.N/H.C No. (%)	H.N/L.C No. (%)	L.N/L.C No. (%)	L.N/H.C No. (%)	Total No. (%)	(χ^2) <i>p</i> value
Age (years)						
≤ 50	28 (21.0)	68 (27.0)	18 (26.0)	2 (25.0)	116 (25.0)	(1.827)
> 50	107 (79.0)	185 (73.0)	51 (74.0)	6 (75.0)	349 (75.0)	0.585
DCIS size						
≤ 20 mm	74 (56.0)	98 (39.0)	31 (45.0)	5 (62.0)	208 (45.0)	(11.087)
> 20 mm	59 (44.0)	155 (61.0)	38 (55.0)	3 (38.0)	255 (55.0)	0.010
DCIS presentation						
Screening	63 (47.0)	129 (51.0)	30 (44.0)	4 (50.0)	226 (49.0)	(1.510)
Symptomatic	72 (53.0)	124 (49.0)	39 (56.0)	4 (50.0)	239 (51.0)	0.673
Nuclear grade						
Low	24 (18.0)	33 (13.0)	4 (6.0)	0 (0.0)	61 (13.0)	(18.978)
Moderate	44 (33.0)	65 (26.0)	10 (14.0)	2 (25.0)	121 (26.0)	0.003
High	67 (50.0)	155 (61.0)	55 (80.0)	6 (75.0)	283 (61.0)	
Comedo necrosis						
No	57 (42.0)	93 (37.0)	16 (23.0)	1 (13.0)	167 (36.0)	(9.173)
Yes	78 (58.0)	160 (63.0)	53 (77.0)	7 (88.0)	298 (64.0)	0.026
Oestrogen receptor						
Negative	23 (18.0)	58 (25.0)	26 (41.0)	5 (62.0)	112 (26.0)	(17.354)
Positive	106 (82.0)	175 (75.0)	38 (59.0)	3 (38.0)	322 (74.0)	0.001
Her2 status						
Negative	107(86.0)	174 (76.0)	38 (62.0)	5 (71.0)	324 (77.0)	(12.831)
Positive	18 (14.0)	56 (24.0)	23 (38.0)	2 (29.0)	99 (23.0)	0.004
Proliferation index (Ki 67)						
Low (≤ 14%)	98 (84.0)	168 (75.0)	42 (69.0)	5 (83.0)	313 (77.0)	(6.455)
High (> 14%)	18 (16.0)	55 (25.0)	19 (31.0)	1 (17.0)	93 (23.0)	0.078
Molecular classes						
Luminal A	64 (58.0)	106 (52.0)	21 (39.0)	0 (0.0)	191 (51.0)	(33.130)
Luminal B	24 (22.0)	45 (22.0)	10 (18.0)	1 (17.0)	80 (21.0)	< 0.001
Her2	5 (5.0)	22 (11.0)	15 (27.0)	1 (17.0)	43 (11.0)	
Triple negative	17 (16.0)	31 (15.0)	8 (15.0)	4 (66.0)	60 (16.0)	

Significant *p*-values are in bold

POLβ DNA polymerase beta, *DCIS* ductal carcinoma in situ, *HER2 Enriched* human epidermal growth factor receptor 2, *H.N/H.C* high nuclear/low cytoplasmic expression, *H.N/L.C* high nuclear/low cytoplasmic expression, *L.N/L.C* low nuclear/low cytoplasmic expression, *L.N/H.C* low nuclear/high cytoplasmic expression

Low *POLβ* nuclear protein level showed significant association with shorter LRFI. A low level of nuclear *POLβ* was associated with recurrence in patients treated with adjuvant radiotherapy and in patients who did not receive radiotherapeutics treatment after BCS. This is a clear signal suggesting that radio-therapeutic treatment does not provide any advantages in DCIS patients with a low level of *POLβ* nuclear protein. More functional studies are required to understand the roles of *POLβ* in DCIS, especially with treatment. In clustering N/C survival, our data showed that the L.N/L.C cluster was the worst group in patient outcomes based on LRFI survival, this observation agrees with the aggressive attribute of low *POLβ* in DCIS.

Low *POLβ* nuclear protein was an independent predictor for all recurrences. Additionally, our preliminary study of *POLβ* depletion in MCF10-DCIS cells suggests that loss of *POLβ* could be associated with increased stemness phenotype in DCIS and hence progression to invasive breast cancer. *POLβ* knockdown cells had a significant increase in NANOG, SOX2, C-MYC and OCT4 which are well-known markers of cancer stem cells. However, overexpression of those markers was not associated with epithelial mesenchymal transition (EMT) as evidence by the no change in N-cadherin and MMP-9 which might have been more significant in a *POLβ* stable knock out cell line model. We anticipate that those changes happen over time DCIS. Therefore,




Fig. 3 Association between POL-β expression and outcome. Kaplan-Meier curves showing low expression of POL-β nuclear protein expression in tumour breast epithelial cells associated with **A** shorter LRFI in all recurrences of pure DCIS cohort. **B** In patients treated

with BCS only. **C** In patients received adjuvant radiotherapy after BCS. **D** Shorter breast cancer specific survival of IBC in the METABRIC cohort. **E, F** Nuclear/cytoplasmic analysis revealed L.N/L.C cluster associated with shorter LRFI

Table 6 Cox regression analysis of POL-β nuclear protein expression in terms of predicting the outcome of local recurrence-free interval (LRFI) in DCIS patients of pure DCIS series treated by breast conserving surgery (BCS)

Parameters	p-value	HR	95% CI	
			Lower	Upper
POL-β Expression	0.031	0.490	0.256	0.936
Age	0.130	1.599	0.871	2.934
Nuclear Grade	0.678	1.096	0.710	1.694
Radiotherapy	0.893	0.942	0.392	2.262
Her2 Status	0.730	0.881	0.429	1.810
Proliferation index (Ki 67)	0.956	0.979	0.453	2.114

All recurrence /Multivariate survival analysis. Significant p-values are in bold

HR Hazard ratio, CI confidence interval, POL-β DNA polymerase beta, DCIS ductal carcinoma in situ, Her2 human epidermal growth factor receptor 2

more work is needed to identify the link between POLβ and stemness phenotype.

The study has some limitations it was carried out using TMA tissue preparations that may underestimate DCIS intratumour heterogeneity. However, full-face tissue sections revealed complete comparability of the heterogeneity of IHC expression. Moreover, the study included a small number of recurrence cases, limited data of patients with recurrence cases who received systemic therapy.

In conclusion, this study has shown the potential role of POLβ as a caretaker and tumour suppressor gene. The data provide evidence that loss or reduced expression of POLβ promotes tumour progression and is most probably associated with the aggressive behaviour of DCIS, which could progress to an invasive stage. Moreover, low POLβ protein level was also associated with a poor outcome within the DCIS. However, further molecular studies are required to further understand the underlying mechanisms.




Fig. 4 POL- β Knockdown and Mechanistic in vitro functional results. Demonstrate POL- β gene KD in day 3, 5 and 7 compared with the control (A). Expression of C-MYC, OCT4, NANOG, SOX2, ALDH1, N-cadherin and MMP-9 protein levels were demonstrating

in MCF10-DCIS_POL β _KD compared with the control MCF10-DCIS (B–H respectively). *p*-values representation: (*) equal to *p*-values $p \leq 0.05$, (**) equal to $p \leq 0.01$ and (***) equal to $p \leq 0.001$

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10549-021-06357-7>.

Acknowledgements This study was supported and funded by the Iraqi Ministry of Higher Education and Scientific Research, Al-Mustansiriya University. We thank Dr Sameer Mirza and Professor Vimla Band for their kind supply of the MCF10 cell lines used in this study. The authors are part of the PathLAKE digital pathology consortium. These new Centres are supported by a £50m investment from the Data to Early Diagnosis and Precision Medicine strand of the government's Industrial Strategy Challenge Fund, managed and delivered by UK Research and Innovation (UKRI).

Data availability The authors confirm the data that has been used in this work are available on reasonable request.

Declarations

Conflict of interest The authors have no conflicts of interest to declare.

Ethical approval All patients included in this study were consented. This work obtained ethics approval by the North West—Greater Manchester Central Research Ethics Committee under the title; Nottingham Health Science Biobank (NHSB), reference number 15/NW/0685. We can declare that this study is complying with Helsinki declaration.

Research involving human participants and/or animals This article does not contain any studies with human participants or animals performed by any of the authors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B, Lei Y, Du S, Vuppalapati A, Luu HH, Haydon RC, He TC, Ren G (2018) Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis* 5(2):77–106. <https://doi.org/10.1016/j.gendis.2018.05.001>
- Wellings SR, Jensen HM (1973) On the origin and progression of ductal carcinoma in the human breast. *J Natl Cancer Inst* 50(5):1111–1118
- Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. *Mol Cell* 40(2):179–204. <https://doi.org/10.1016/j.molcel.2010.09.019>

4. Ali R, Rakha EA, Madhusudan S, Bryant HE (2017) DNA damage repair in breast cancer and its therapeutic implications. *Pathology* 49(2):156–165. <https://doi.org/10.1016/j.pathol.2016.11.002>
5. Wilson DM 3rd, Bohr VA (2007) The mechanics of base excision repair, and its relationship to aging and disease. *DNA Repair (Amst)* 6(4):544–559. <https://doi.org/10.1016/j.dnarep.2006.10.017>
6. Dianov GL, Hubscher U (2013) Mammalian base excision repair: the forgotten archangel. *Nucleic Acids Res* 41(6):3483–3490. <https://doi.org/10.1093/nar/gkt076>
7. Kim YJ, Wilson DM 3rd (2012) Overview of base excision repair biochemistry. *Curr Mol Pharmacol* 5(1):3–13
8. Servant L, Bieth A, Hayakawa H, Cazaux C, Hoffmann JS (2002) Involvement of DNA polymerase beta in DNA replication and mutagenic consequences. *J Mol Biol* 315(5):1039–1047. <https://doi.org/10.1006/jmbi.2001.5307>
9. Canitrot Y, Cazaux C, Frechet M, Bouayadi K, Lesca C, Salles B, Hoffmann JS (1998) Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. *Proc Natl Acad Sci USA* 95(21):12586–12590
10. Bergoglio V, Bavoux C, Verbiest V, Hoffmann JS, Cazaux C (2002) Localisation of human DNA polymerase kappa to replication foci. *J Cell Sci* 115(Pt 23):4413–4418
11. Svilar D, Goellner EM, Almeida KH, Sobol RW (2011) Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. *Antioxid Redox Signal* 14(12):2491–2507. <https://doi.org/10.1089/ars.2010.3466>
12. Masaoka A, Horton JK, Beard WA, Wilson SH (2009) DNA polymerase beta and PARP activities in base excision repair in living cells. *DNA Repair (Amst)* 8(11):1290–1299. <https://doi.org/10.1016/j.dnarep.2009.08.004>
13. Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW (2011) N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide. *Neuro Oncol* 13(5):471–486. <https://doi.org/10.1093/neuonc/nor011>
14. Jelezcova E, Trivedi RN, Wang XH, Tang JB, Brown AR, Goellner EM, Schamus S, Fornasaglio JL, Sobol RW (2010) Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage. *Mutat Res* 686(1–2):57–67. <https://doi.org/10.1016/j.mrfmmm.2010.01.016>
15. Tan X, Wang H, Luo G, Ren S, Li W, Cui J, Gill HS, Fu SW, Lu Y (2015) Clinical significance of a point mutation in DNA polymerase beta (POLB) gene in gastric cancer. *Int J Biol Sci* 11(2):144–155. <https://doi.org/10.7150/ijbs.10692>
16. Abdel-Fatah TM, Russell R, Agarwal D, Moseley P, Abayomi MA, Perry C, Albarakati N, Ball G, Chan S, Caldas C, Ellis IO, Madhusudan S (2014) DNA polymerase beta deficiency is linked to aggressive breast cancer: a comprehensive analysis of gene copy number, mRNA and protein expression in multiple cohorts. *Mol Oncol* 8(3):520–532. <https://doi.org/10.1016/j.molonc.2014.01.001>
17. Zhao GQ, Wang T, Zhao Q, Yang HY, Tan XH, Dong ZM (2005) Mutation of DNA polymerase beta in esophageal carcinoma of different regions. *World J Gastroenterol* 11(30):4618–4622
18. Pole JC, Courtay-Cahen C, Garcia MJ, Blood KA, Cooke SL, Alsop AE, Tse DM, Caldas C, Edwards PA (2006) High-resolution analysis of chromosome rearrangements on 8p in breast, colon and pancreatic cancer reveals a complex pattern of loss, gain and translocation. *Oncogene* 25(41):5693–5706. <https://doi.org/10.1038/sj.onc.1209570>
19. Venter DJ, Ramus SJ, Hammet FM, de Silva M, Hutchins AM, Petrovic V, Price G, Armes JE (2005) Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines. *Cancer Genet Cytogenet* 160(2):134–140. <https://doi.org/10.1016/j.cancergencyto.2004.12.007>
20. Osheroff WP, Beard WA, Yin S, Wilson SH, Kunkel TA (2000) Minor groove interactions at the DNA polymerase beta active site modulate single-base deletion error rates. *J Biol Chem* 275(36):28033–28038. <https://doi.org/10.1074/jbc.M003462200>
21. Shah AM, Li SX, Anderson KS, Sweasy JB (2001) Y265H mutator mutant of DNA polymerase beta. Proper tetrametric alignment is critical for fidelity. *J Biol Chem* 276(14):10824–10831. <https://doi.org/10.1074/jbc.M008680200>
22. Maitra M, Gudzelak A Jr, Li SX, Matsumoto Y, Eckert KA, Jager J, Sweasy JB (2002) Threonine 79 is a hinge residue that governs the fidelity of DNA polymerase beta by helping to position the DNA within the active site. *J Biol Chem* 277(38):35550–35560. <https://doi.org/10.1074/jbc.M204953200>
23. Miligy IM, Gorringer KL, Toss MS, Al-Kawaz AA, Simpson P, Diez-Rodriguez M, Nolan CC, Ellis IO, Green AR, Rakha EA (2018) Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ. *Mod Pathol* 31(12):1807–1815. <https://doi.org/10.1038/s41379-018-0086-7>
24. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FCG, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol* 28(16):2784–2795. <https://doi.org/10.1200/JCO.2009.25.6529>
25. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO (2015) Updated UK Recommendations for HER2 assessment in breast cancer. *J Clin Pathol* 68(2):93–99. <https://doi.org/10.1136/jclinpath-2014-202571>
26. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Lanigerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowitz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* 486(7403):346–352. <https://doi.org/10.1038/nature10983>
27. Chrysanthou E, Gorringer KL, Joseph C, Craze M, Nolan CC, Diez-Rodriguez M, Green AR, Rakha EA, Ellis IO, Mukherjee A (2017) Phenotypic characterisation of breast cancer: the role of CDC42. *Breast Cancer Res Treat* 164(2):317–325. <https://doi.org/10.1007/s10549-017-4267-8>
28. Camp RL, Dolled-Fillhart M, Rimm DL (2004) X-tile: a new bioinformatics tool for biomarker assessment and outcome-based cut-point optimization. *Clin Cancer Res* 10(21):7252–7259. <https://doi.org/10.1158/1078-0432.ccr-04-0713>
29. Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. *PLoS ONE* 7(12):e51862. <https://doi.org/10.1371/journal.pone.0051862>
30. Band V, Sager R (1989) Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. *Proc Natl Acad Sci USA* 86(4):1249–1253. <https://doi.org/10.1073/pnas.86.4.1249>
31. Miller FR, Santner SJ, Tait L, Dawson PJ (2000) MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ.

- JNCI 92(14):1185a–11186. <https://doi.org/10.1093/jnci/92.14.1185a>
32. Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S (2018) Targeting PARP1 in XRCC1-deficient sporadic invasive breast cancer or preinvasive ductal carcinoma in situ induces synthetic lethality and chemoprevention. *Cancer Res* 78(24):6818–6827. <https://doi.org/10.1158/0008-5472.can-18-0633>
 33. Chantre-Justino M, Alves G, Britto C, Cardoso A, Scherrer L, Moreira Ados S, Quirino R, Ornellas A, Leitao A, Lage C (2015) Impact of reduced levels of APE1 transcripts on the survival of patients with urothelial carcinoma of the bladder. *Oncol Rep* 34(4):1667–1674. <https://doi.org/10.3892/or.2015.4151>
 34. Sweasy JB, Lang T, Starcevic D, Sun KW, Lai CC, Dimaio D, Dalal S (2005) Expression of DNA polymerase beta cancer-associated variants in mouse cells results in cellular transformation. *Proc Natl Acad Sci USA* 102(40):14350–14355. <https://doi.org/10.1073/pnas.0505166102>
 35. Bhattacharyya N, Chen HC, Comhair S, Erzurum SC, Banerjee S (1999) Variant forms of DNA polymerase beta in primary lung carcinomas. *DNA Cell Biol* 18(7):549–554. <https://doi.org/10.1089/104454999315097>
 36. Wang L, Patel U, Ghosh L, Banerjee S (1992) DNA polymerase beta mutations in human colorectal cancer. *Cancer Res* 52(17):4824–4827
 37. Abramenko I, Bilous N, Chumak A, Kostin A, Martina Z, Dyagil I (2012) DNA repair polymorphisms in B-cell chronic lymphocytic leukemia in sufferers of chernobyl nuclear power plant accident. *J Radiat Res* 53(3):497–503
 38. Starcevic D, Dalal S, Sweasy JB (2004) Is there a link between DNA polymerase beta and cancer? *Cell Cycle* 3(8):998–1001
 39. Yamtich J (1804) Sweasy JB (2010) DNA polymerase family X: function, structure, and cellular roles. *Biochim Biophys Acta* 5:1136–1150. <https://doi.org/10.1016/j.bbapap.2009.07.008>
 40. Cabelof DC, Raffoul JJ, Yanamadala S, Guo Z, Heydari AR (2002) Induction of DNA polymerase beta-dependent base excision repair in response to oxidative stress in vivo. *Carcinogenesis* 23(9):1419–1425. <https://doi.org/10.1093/carcin/23.9.1419>
 41. Albertella MR, Lau A, O'Connor MJ (2005) The overexpression of specialized DNA polymerases in cancer. *DNA Repair (Amst)* 4(5):583–593. <https://doi.org/10.1016/j.dnarep.2005.01.005>
 42. Mobley JA, Brueggemeier RW (2004) Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. *Carcinogenesis* 25(1):3–9. <https://doi.org/10.1093/carcin/bgg175>
 43. Musarrat J, Arezina-Wilson J, Wani AA (1996) Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. *Eur J Cancer (Oxford, England: 1990)* 32a(7):1209–1214
 44. Bhat HK, Calaf G, Hei TK, Loya T, Vadgama JV (2003) Critical role of oxidative stress in estrogen-induced carcinogenesis. *Proc Natl Acad Sci USA* 100(7):3913–3918. <https://doi.org/10.1073/pnas.0437929100>
 45. Xu Y, Chen M, Liu C, Zhang X, Li W, Cheng H, Zhu J, Zhang M, Chen Z, Zhang B (2017) Association study confirmed three breast cancer-specific molecular subtype-associated susceptibility loci in Chinese Han women. *Oncologist* 22(8):890–894. <https://doi.org/10.1634/theoncologist.2016-0423>
 46. Freudenberg JA, Wang Q, Katsumata M, Drebin J, Nagatomo I, Greene MI (2009) The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. *Exp Mol Pathol* 87(1):1–11. <https://doi.org/10.1016/j.yexmp.2009.05.001>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.